


| | | | | | |
|---|--|--|--|---|--------------------------------------|
| Form PTO-1449 | | U.S. Department of Commerce Patent and Trademark Office | | Atty. Docket No. 75723-ZA/JPW/GJG | U.S. Serial No. 10/037,341 |
| INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) | | | | Applicants David Baltimore et al. | |
| | | | | Filing Date January 4, 2002 | Page 1 of 6 |



| U.S. PATENT DOCUMENTS | | | | | | | | | | | | | |
|------------------------------|---|---|---|---|---|---|---|---|----------|----------------|-------|----------|----------------------------|
| Examiner Initial | 1 | 4 | 6 | 8 | 4 | 6 | 2 | 3 | Date | Name | Class | Subclass | Filing Date if Appropriate |
| | 1 | 4 | 6 | 8 | 4 | 6 | 2 | 3 | 8/4/87 | Larrick et al. | | | |
| | 2 | 5 | 6 | 5 | 8 | 8 | 0 | 3 | 8/19/97 | Kuo | | | |
| | 3 | 5 | 6 | 9 | 8 | 4 | 1 | 9 | 12/16/97 | Wolpe et al. | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | | | | | | | | |
|---------------------------------|---|---|---|---|---|---|---|------|---------|-------|----------|-------------|-----|----|
| 1 | 4 | 6 | 8 | 4 | 6 | 2 | 3 | Date | Country | Class | Subclass | Translation | | |
| | 4 | 8 | 9 | 0 | 7 | 6 | 1 | 4 | 8/24/89 | PCT | | | Yes | No |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | |
|---|--|
| 5 | Beutler, B. et al., "Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin", Science (1985) 229:869-871 |
| 6 | Beutler, B. and Cerami, A., "Cachectin: More Than A Tumor Necrosis Factor", The New England Journal of Medicine (1987) 316:379-385 |
| 7 | Beutler, B. and Cerami, A., "Tumor Necrosis, Cachexia, Shock, And Inflammation: A Common Mediator", Ann. Rev. Biochem. (1988) 57:505-18 |
| 8 | Blasco, R. et al., "Variable and Constant Regions in African Swine Fever Virus DNA", Virology (1989) 168:330-338 |
| 9 | Brady, J. et al., "Interaction between two transcriptional control sequences required for tumor-antigen-mediated simian virus 40 late gene expression", Proc. Natl. Acad. Sci. USA (1985) 82:7299-7303 |

| | |
|-----------------|------------------------|
| EXAMINER | DATE CONSIDERED |
|-----------------|------------------------|

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicants: D. Baltimore, et al.
 Serial No.: 10/037,341
 Filed: January 4, 2002
 Exhibit B

| | | | | | | | |
|--|----|--|------|---|-------|-------------------------------|--------------------------------|
| Form PTO-1449 | | U.S. Department of Commerce Patent and Trademark Office | | Atty. Docket No. 75723-ZA/JPW/GJG | | U.S. Serial No. 10/037,341 | |
| INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) | | | | Applicants David Baltimore et al. | | | |
| | | | | Filing Date January 4, 2002 | | Page 2 of 6 | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| Examiner Initial | | Document Number | Date | Name | Class | Subclass | Filing Date if Appropriate |
| | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | | Document Number | Date | Country | Class | Subclass | Translat ion Yes No |
| | | | | | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | |
| | 10 | Brady, J. and Khoury, G., "trans Activation of the Simian Virus 40 Late Transcription Unit by T-Antigen", Molecular and Cellular Biology (1985) 5:1391-1399 | | | | | |
| | 11 | Enjuanes, L. et al., "Titration of African Swine Fever (ASF) Virus", J. Gen. Virol. (1976) 32:471-477 | | | | | |
| | 12 | Enjuanes, L. et al., "Isolation and Properties of the DAN of African Swine Fever (ASF) Virus", J. Gen. Virol. (1976) 32:479-492 | | | | | |
| | 13 | Fendly, B.M. et al., "Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor", Hybridoma (1987) 6:359-370 | | | | | |
| | 14 | Israel, A. et al., "A common positive trans-acting factor binds to enhancer sequence in the promoters of mouse H-2 and β_2 -microglobulin genes", Proc. Natl. Acad. Sci. USA (1987) 84:2653-2657 | | | | | |
| EXAMINER | | | | DATE CONSIDERED | | | |
| *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | |

| | | | | | | | | |
|---|--|--|--|--|---|--|--------------------------------------|--|
| Form PTO-1449 | | U.S. Department of Commerce Patent and Trademark Office | | | Atty. Docket No. 75723-ZA/JPW/GJG | | U.S. Serial No. 10/037,341 | |
| INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) | | | | | Applicants David Baltimore et al. | | | |
| | | | | | Filing Date January 4, 2002 | | Page 3 of 6 | |

| U.S. PATENT DOCUMENTS | | | | | | | | | |
|-----------------------|--|-----------------|------|------|-------|----------|----------------------------|--|--|
| Examiner Initial | | Document Number | Date | Name | Class | Subclass | Filing Date if Appropriate | | |
| | | | | | | | | | |
| | | | | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | | | |
|--------------------------|--|-----------------|------|---------|-------|----------|-------------|-----|----|
| | | Document Number | Date | Country | Class | Subclass | Translation | | |
| | | | | | | | | Yes | No |
| | | | | | | | | | |
| | | | | | | | | | |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | |
|--|---|
| 15 | Israël, A. et al., "TNF stimulates expression of mouse MHC class I genes by inducing an Nf κ B-like enhancer binding activity which displaces constitutive factors", The EMBO Journal (1989) 8:3793-3800 |
| 16 | Lenardo, M.J. and Baltimore, D., "NF- κ B: A Pleiotropic Mediator of Inducible and Tissue-Specific Gene Control", Cell (1989) 58:227-229 |
| 17 | Meager, A. et al., "Preparation and Characterization of Monoclonal Antibodies Directed Against Antigenic Determinants of Recombinant Human Tumour Necrosis Factor (rTNF)", Hybridoma (1987) 6:305-311 |
| 18 | Mercola, M. et al., "Immunoglobulin Heavy-Chain Enhancer Requires One or More Tissue-Specific Factors", Science (1985) 227:266-270 |
| 19 | Rothlein, R. et al., "Induction of Intercellular Adhesion Molecule 1 on Primary And Continuous Cell Lines By Pro-Inflammatory Cytokines", The Journal of Immunology (1988) 141:1665-1669 |

| | |
|----------|-----------------|
| EXAMINER | DATE CONSIDERED |
|----------|-----------------|

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | | | | | | |
|---|--|--|--|---|--|--------------------------------------|--|
| Form PTO-1449 | | U.S. Department of Commerce Patent and Trademark Office | | Atty. Docket No. 75723-ZA/JPW/GJG | | U.S. Serial No. 10/037,341 | |
| INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) | | | | Applicants David Baltimore et al. | | | |
| | | | | Filing Date January 4, 2002 | | Page 4 of 6 | |

| U.S. PATENT DOCUMENTS | | | | | | | | | |
|------------------------------|--|-----------------|------|------|-------|----------|----------------------------|--|--|
| Examiner Initial | | Document Number | Date | Name | Class | Subclass | Filing Date if Appropriate | | |
| | | | | | | | | | |
| | | | | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | | | |
|---------------------------------|--|-----------------|------|---------|-------|----------|-------------|----|--|
| | | Document Number | Date | Country | Class | Subclass | Translation | | |
| | | | | | | | Yes | No | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
|---|--|--|
| 20 | | Schöler, H.R. and Gruss, P., "Specific Interaction between Enhancer-Containing Molecules and Cellular Components", Cell (1984) 36:403-411 |
| 21 | | Singh, H. et al., "A nuclear factor that binds to a conserved sequence motif in transcriptional control elements of immunoglobulin genes", Nature (1986) 319:154-158 |
| 22 | | September 13, 2007 Order, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT |
| 23 | | September 20, 2007 Amgen Entities' Amended Response And Objections To Ariad's Interrogatory No. 12, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT |
| 24 | | September 21, 2007 Wyeth's Third Set of Supplemental Responses And Objections To Ariad's First Set of Interrogatories (Nos. 1-25), Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT |

| | |
|-----------------|------------------------|
| EXAMINER | DATE CONSIDERED |
|-----------------|------------------------|

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | | | | | | |
|---|----|---|------------------------|---|-------|---------------------------------------|----------------------------|
| Form PTO-1449 | | U.S. Department of Commerce Patent and Trademark Office | | Atty. Docket No. 75723-ZA/JPW/GJG | | U.S. Serial No. 10/037,341 | |
| INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) | | | | Applicants David Baltimore et al. | | Filing Date January 4, 2002 | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| Examiner Initial | | Document Number | Date | Name | Class | Subclass | Filing Date if Appropriate |
| | | | | | | | |
| | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | | Document Number | Date | Country | Class | Subclass | Translation |
| | | | | | | | Yes No |
| | | | | | | | |
| | | | | | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | |
| | 25 | September 24, 2007 Answer To Amended Complaint, Amended Counterclaim and Demand For Jury Trial, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT | | | | | |
| | 26 | September 26, 2007 Deposition of David Baltimore including Exhibits 169-178, 1008-1016, 1, 11, 12, 57, 146, 1002 and 1004, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT | | | | | |
| | 27 | October 3, 2007 Videotaped Deposition of Tom Maniatis, Ph.D. including Exhibits 1, 11-12, 31-32, 35-36, 78, 179-189 and 191-194, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT | | | | | |
| | 28 | October 4, 2007 continued Videotaped Deposition of Tom Maniatis, Ph.D. including Exhibits 1, 11-12, 31-32, 35-36, 78, 195-196, 1017-1022, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT | | | | | |
| EXAMINER | | | DATE CONSIDERED | | | | |
| <small>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small> | | | | | | | |

| | | | | | | | | |
|---|--|--|--|--|---|--|-------------------------------|--|
| Form PTO-1449 | | U.S. Department of Commerce Patent and Trademark Office | | | Atty. Docket No. 75723-ZA/JPW/GJG | | U.S. Serial No. 10/037,341 | |
| INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) | | | | | Applicants David Baltimore et al. | | | |
| | | | | | Filing Date January 4, 2002 | | Page 6 of 6 | |

| U.S. PATENT DOCUMENTS | | | | | | | | | |
|-----------------------|--|-----------------|------|------|-------|----------|----------------------------|--|--|
| Examiner Initial | | Document Number | Date | Name | Class | Subclass | Filing Date if Appropriate | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | | | |
|--------------------------|--|-----------------|------|---------|-------|----------|-------------|-----|----|
| | | Document Number | Date | Country | Class | Subclass | Translation | | |
| | | | | | | | | Yes | No |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
|--|--|--|
| 29 | | October 9, 2007 Amgen Entities' Reply to Ariad, Harvard, MIT, And Whitehead's Amended Counterclaim, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT |
| 30 | | October 9, 2007 Wyeth's Reply To Ariad Pharmaceuticals, Inc., Massachusetts Institute of Technology, The President And Fellows of Harvard College, And The Whitehead Institute for Biomedical Research's Amended Counterclaim, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT |
| 31 | | October 31, 2007 Wyeth's Fourth Set of Supplemental Responses And Objections To Ariad's First Set of Interrogatories (Nos. 1-25), Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT |
| | | |
| | | |

| | |
|-----------------|------------------------|
| EXAMINER | DATE CONSIDERED |
|-----------------|------------------------|

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.